[1]
Z. Lechowska, “NATALIZUMAB IN MULTIPLE SCLEROSIS – A REVIEW OF DIFFERENT DOSING REGIMENS, SIDE EFFECTS, COMPARISON WITH OTHER DISEASE-MODIFYING THERAPIES WITH ADDITIONAL ATTENTION TO USE IN PREGNANCY AND THE PEDIATRIC POPULATION”, IJITSS, vol. 2, no. 3(51), Aug. 2026, doi: 10.31435/ijitss.3(51).2026.5801.